Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the real-world effectiveness of angiotensin receptor-neprilysin inhibitor ARNi therapy compared to antihypertensive monotherapy in lowering blood pressure among adults with hypertension in the United Arab Emirates. The study focuses on patients diagnosed with hypertension and aims to see how these treatments impact blood pressure control in everyday clinical settings. The study includes two groups one group starts or switches to ARNi treatment sacubitrilvalsartan, and the other begins antihypertensive monotherapy with either an ACE inhibitor, an ARB, or a calcium channel blocker. Patients will be observed as they receive these therapies according to their physicians direction. Participants will have their blood pressure measured at the start and during follow-up visits, with primary measurement focused on the change in mean sitting systolic blood pressure from baseline to week 4. Additional measures include diastolic blood pressure, pulse pressure, and the proportion of patients reaching target blood pressure at weeks 4 and 12. The study will continue until August 2027, with assessments occurring at these defined timepoints to monitor treatment effects and safety.
Actively Recruiting
Researchers are studying the effects of dupilumab treatment on mental health, specifically anxiety and depression symptoms, as well as quality of life in patients with moderate-to-severe atopic dermatitis AD. The study focuses on patients already receiving dupilumab, aiming to observe how this treatment impacts their psychological well-being and life quality over time. Participants will be observed during a 6-month period while continuing their dupilumab therapy as prescribed by their doctors in real-world clinical settings. The study does not administer any treatments but monitors patients who start dupilumab within 30 days before enrollment. The enrollment period for the study will last about 9 months. Throughout the study, participants will complete assessments measuring anxiety and depression levels using the Hospital Anxiety and Depression Scale HADS and quality of life via tools like the Patient-Oriented Eczema Measure POEM and Dermatology Life Quality Index DLQI. Researchers will evaluate changes from baseline to week 24 in these scores and monitor professional and psychological impacts. The study aims to better understand the mental health outcomes of patients receiving dupilumab over six months.